Jonathan S. Marshall
BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Carbon dioxide equivalent emissions and cost impact of non-clinically driven inhaler initiation or switch for COPD.
Journal: Current medical research and opinion
Published: February 23, 2026
Response to the Letter to the Editor by Zambelli et al for In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients With COPD Using Functional Respiratory Imaging [Response To Letter].
Journal: International journal of chronic obstructive pulmonary disease
Published: January 20, 2026
Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease.
Journal: Journal of comparative effectiveness research
Published: December 15, 2025
Letter to the Editor Regarding "Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy".
Journal: Advances in therapy
Published: September 26, 2025
Prompt initiation of single-inhaler budesonide/glycopyrrolate/formoterol fumarate (BGF) following a COPD exacerbation reduces exacerbations and cardiopulmonary risk in patients with COPD: insights from the MITOS EROS+CP study in the United States.
Journal: Current medical research and opinion
Published: August 11, 2025
Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS/AVOIDEX programme.
Journal: BMJ open
Published: July 24, 2025
Current Smoking and Pharmacological Treatment Responses in Chronic Obstructive Pulmonary Disease: Not Clear-Cut.
Journal: American journal of respiratory and critical care medicine
Published: July 18, 2025
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS.
Journal: Respiratory medicine
Published: June 12, 2025
Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial.
Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)
Published: April 29, 2025
In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients with COPD Using Functional Respiratory Imaging.
Journal: International journal of chronic obstructive pulmonary disease
Published: December 13, 2024
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS.
Journal: Respiratory research
Published: December 10, 2024
Last Updated: 09/26/2026